16.16
7.16%
1.08
시장 영업 전:
15.99
-0.17
-1.05%
전일 마감가:
$15.08
열려 있는:
$15.38
하루 거래량:
1.66M
Relative Volume:
0.90
시가총액:
$1.96B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-8.00
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
+4.66%
1개월 성능:
+15.10%
6개월 성능:
-3.23%
1년 성능:
-61.34%
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
16.16 | 1.96B | 631.73M | -239.78M | -33.45M | -2.02 |
VEEV
Veeva Systems Inc
|
223.04 | 36.21B | 2.66B | 665.91M | 1.08B | 4.05 |
SOLV
Solventum Corp
|
74.02 | 12.79B | 8.26B | 66.00M | 1.17B | 0.3682 |
DOCS
Doximity Inc
|
55.52 | 10.37B | 516.85M | 174.11M | 217.38M | 0.87 |
HQY
Healthequity Inc
|
104.74 | 9.08B | 1.15B | 96.70M | -161.99M | 1.09 |
TEM
Tempus Ai Inc
|
47.64 | 7.50B | 640.44M | -743.28M | -206.93M | -11.29 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-09-03 | 개시 | Leerink Partners | Outperform |
2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
2024-06-03 | 재개 | Jefferies | Hold |
2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
2023-12-14 | 개시 | Guggenheim | Buy |
2023-12-13 | 개시 | Wolfe Research | Outperform |
2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
2023-07-05 | 재개 | JP Morgan | Overweight |
2023-05-10 | 개시 | Barclays | Overweight |
2023-03-31 | 개시 | Stephens | Overweight |
2023-02-02 | 개시 | UBS | Neutral |
2022-12-14 | 개시 | Deutsche Bank | Buy |
2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
2022-07-25 | 개시 | Canaccord Genuity | Buy |
2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2021-10-15 | 재개 | Cowen | Outperform |
2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
2021-03-15 | 개시 | William Blair | Outperform |
2020-12-02 | 개시 | Goldman | Neutral |
2020-09-09 | 개시 | Morgan Stanley | Overweight |
2020-07-10 | 개시 | Stifel | Buy |
2020-03-05 | 개시 | Guggenheim | Buy |
2020-01-07 | 개시 | Citigroup | Buy |
2019-10-07 | 개시 | BofA/Merrill | Buy |
2019-10-07 | 개시 | Cowen | Outperform |
2019-10-07 | 개시 | JP Morgan | Overweight |
2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
Weiss Ratings Reaffirms Sell (E+) Rating for 10x Genomics (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Preferred Stock : $0.0 Mil (As of Sep. 2024) - GuruFocus.com
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
Avanza Fonder AB Takes Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TXG (10x Genomics) Future Policy Benefits - GuruFocus.com
TXG (10x Genomics) EBIT per Share : $-1.47 (TTM As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Shareholder Yield % : 0.44% (As of Sep. 2024) - GuruFocus.com
TXG (10x Genomics) Earnings Yield (Joel Greenblatt) % : -7.27% (As of Sep. 2024) - GuruFocus.com
10x Genomics (NASDAQ:TXG) Trading Down 4.9%What's Next? - MarketBeat
Assenagon Asset Management S.A. Makes New $26.31 Million Investment in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (FRA:1KJ) Days Sales Outstanding : 53.41 (As of Sep. 2024) - GuruFocus.com
Mirador Capital Partners LP Boosts Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
The Analyst Verdict: 10x Genomics In The Eyes Of 6 Experts - Benzinga
JPMorgan Chase & Co. Has $8.03 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (NASDAQ:TXG) Shares Gap UpTime to Buy? - MarketBeat
Morgan Stanley Issues Pessimistic Forecast for 10x Genomics (NASDAQ:TXG) Stock Price - MarketBeat
JPM25: 10X Genomics $TXGby AlbertRhymes with Haystack - substack.com
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results - The Malaysian Reserve
10x Genomics Q4 Revenue Hits $165M with Mixed Results: Services Surge 35% YoY Despite Overall Decline - StockTitan
Diversified Trust Co Invests $511,000 in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting - Kilgore News Herald
10x Genomics: Struggling Amid Operational Challenges (NASDAQ:TXG) - Seeking Alpha
Vizgen Loses Antitrust Claims Against 10x In Biotech IP Fight - Law360
10x Genomics (NASDAQ:TXG) Shares Up 11.6%Here's What Happened - MarketBeat
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StreetInsider.com
10x Genomics to Present at the 43rd Annual J.P. Morgan Healthcare Conference – Company Announcement - Financial Times
10x Genomics to Present at J.P. Morgan Healthcare Conference Next Week - StockTitan
10x Genomics, Inc. (NASDAQ:TXG) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Cathie Wood's ARK ETF adjusts, adds 10X Genomics, sells Rocket Lab - Investing.com
Geode Capital Management LLC Boosts Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics wins permanent injunction against NanoString - MSN
10x Genomics secures injunction against Bruker By Investing.com - Investing.com Australia
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products - The Malaysian Reserve
10x’s $31 Million Verdict Stands and NanoString’s GeoMx Blocked - Bloomberg Law
U.S. District Court Awards 10x Genomics Permanent Injunction in - GuruFocus.com
10x Genomics secures injunction against Bruker - Investing.com India
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products – Company AnnouncementFT.com - Financial Times
U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation's GeoMx Products (PR Newswire) - Aktiellt
10x Genomics (NASDAQ:TXG) Trading Up 4.3%Should You Buy? - MarketBeat
State Street Corp Increases Stock Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Goldman Sachs Maintains 10x Genomics Inc(TXG) Sell Recommendation - MSN
10X Genomics' SWOT analysis: genomics firm navigates challenges, eyes recovery - Investing.com
Insider Sellers Might Regret Selling 10x Genomics Shares at a Lower Price Than Current Market Value - Simply Wall St
Barclays PLC Has $13.61 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10X Genomics' SWOT analysis: genomics firm's stock faces instrument demand headwinds - Investing.com
XTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Reports Third Quarter 2024 Financial Results - The Eastern Progress Online
46,029 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Weiss Asset Management LP - MarketBeat
Quantinno Capital Management LP Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
Charles Schwab Investment Management Inc. Has $14.71 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (FRA:1KJ) Current Ratio : 4.90 (As of Sep. 2024) - GuruFocus.com
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):